Penumbra Inc (PEN) company profile
Close on Nov 17, 2026Market cap $12.58BP/E 80.4Yield –
About Penumbra
Surgical & Medical Instruments & Apparatus, SIC 3841
Penumbra develops and manufactures medical devices designed to address challenging vascular conditions throughout the body, operating as a single segment focused on thrombectomy, embolization, and access solutions. The company's thrombectomy portfolio includes computer-assisted vacuum aspiration systems, continuous aspiration mechanical catheters, and reperfusion devices used to treat ischemic stroke, pulmonary embolism, deep vein thrombosis, and acute limb ischemia. In addition, it produces peripheral and neurovascular embolization devices, such as detachable coils and occlusion systems, alongside guide and intermediate access catheters and neurosurgical evacuation tools. Penumbra primarily sells these products directly to healthcare providers and hospital systems for use by specialist physicians, including interventional radiologists, neuroradiologists, vascular surgeons, neurosurgeons, and interventional cardiologists.
The enterprise maintains direct commercial sales forces across the United States, Canada, Australia, Singapore, and most European nations, supplemented by independent distributors in other international territories and a licensing partner in China. It conducts research, development, and manufacturing operations in Alameda and Roseville, California.
Summary of the business section of Penumbra's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Penumbra Inc
- Founded
- 2004
- Headquarters
- Alameda, CA
- Address
- One Penumbra Place 94502
- Phone
- (510) 995-2486
- Website
- www.penumbrainc.com
- Employees
- 4,700, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, San Francisco, California
Stock & identifiers
- Ticker
- PEN
- Exchange
- NYSE
- IPO date
- Sep 18, 2015
- Shares outstanding
- 39M, Oct 14, 2026
- Public float
- $9.70B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1321732
- CUSIP
- 70975L107
- ISIN
- US70975L1070
- FIGI
- BBG001BP92V1
- Share class FIGI
- BBG001TRHPB0
- LEI
- 549300RGE06P3ECANU72
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Adam Elsesser | CEO, Director | 865,502 |
| Maggie Yuen | Chief Financial Officer | 20,563 |
| Lambert Shiu | Chief Accounting Officer | 41,976 |
| Johanna Roberts | EVP, Gen. Counsel & Secretary | 69,416 |
| Shruthi Narayan | President | 31,283 |
| Harpreet Grewal | Director | 8,719 |
| Thomas Wilder | Director | 5,095 |
| Bridget O'Rourke | Director | 5,962 |
| Arani Bose | Director | 259,609 |
| Janet Leeds | Director | 6,639 |
| Surbhi Sarna | Director | 4,293 |
| Don W. Kassing | Director | 9,909 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $851.62K | $851.62K | $2.85M | $178 | $78 |
| FY2024 | $630.47K | $630.47K | $1.84M | $136 | $78 |
| FY2023 | $601.62K | $601.62K | $622.62K | $144 | $74 |
| FY2022 | $601.62K | $601.62K | $1.78M | $127 | $79 |
| FY2021 | $497.79K | $497.79K | $1.31M | $164 | $103 |
| FY2020 | $219.03K | $219.03K | $475.77K | $107 | $133 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|
| Adam Elsesser Chief Executive Officer and former President | $850.00K | – | $1.62K | $851.62K | +35% |
| Maggie Yuen Chief Financial Officer | $715.39K | $1.71M | $7.08K | $2.43M | +37% |
| Johanna Roberts Executive Vice President, General Counsel and Secretary | $715.39K | $1.71M | $6.99K | $2.43M | +11% |
| Lambert Shiu Chief Accounting Officer | $594.23K | $1.58M | $6.91K | $2.18M | +39% |
| Shruthi Narayan President | $730.77K | $3.64M | $6.58K | $4.38M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Sep 18, 2015
- Offer price
- $30.00
- Securities offered
- 4,000,000
- Gross proceeds
- $120.00M
- Exchange
- NYSE
- First trading day
- Sep 18, 2015
- First-day close
- $41.30+37.7%
- Lock-up ends (est.)
- Mar 16, 2016
“The initial public offering price of our common stock is $30.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had approximately 4,700 employees worldwide.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 1, 2026 | Merger vote | Definitive merger proxy statement |
| Mar 21, 2024 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Oct 7, 2021 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Sep 4, 2018 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jul 10, 2017 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Sep 18, 2015 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 15, 2015 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?